Epitranscriptomics of ischemic heart disease-the IHD-EPITRAN study design and objectives

Sikorski, Vilbert
Karjalainen, Pasi
Blokhina, Daria
Oksaharju, Kati
Khan, Jahangir
Katayama, Shintaro
Rajala, Helena
Suihko, Satu
Tuohinen, Suvi
Teittinen, Kari
Nummi, Annu
Nykänen, Antti
Eskin, Arda
Stark, Christoffer
Biancari, Fausto
Kiss, Jan
Simpanen, Jarmo
Ropponen, Jussi
Lemström, Karl
Savinainen, Kimmo
Lalowski, Maciej
Kaarne, Markku
Jormalainen, Mikko
Elomaa, Outi
Koivisto, Pertti
Raivio, Peter
Bäckström, Pia
Dahlbacka, Sebastian
Syrjälä, Simo
Vainikka, Tiina
Vähäsilta, Tommi
Tunçbağ, Nurcan
Karelson, Mati
Mervaala, Eero
Juvonen, Tatu
Laine, Mika
Laurikka, Jari
Vento, Antti
Kankuri, Esko
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.Epitranscriptomic modifications in RNA can dramatically alter the way our genetic code is deciphered. Cells utilize these modifications not only to maintain physiological processes, but also to respond to extracellular cues and various stressors. Most often, adenosine residues in RNA are targeted, and result in modifications including methylation and deamination. Such modified residues as N-6-methyl-adenosine (m6A) and inosine, respectively, have been associated with cardiovascular diseases, and contribute to disease pathologies. The Ischemic Heart Disease Epitranscriptomics and Biomarkers (IHD-EPITRAN) study aims to provide a more comprehensive understanding to their nature and role in cardiovascular pathology. The study hypothesis is that pathological features of IHD are mirrored in the blood epitranscriptome. The IHD-EPITRAN study focuses on m6A and A-to-I modifications of RNA. Patients are recruited from four cohorts: (I) patients with IHD and myocardial infarction undergoing urgent revascularization; (II) patients with stable IHD undergoing coronary artery bypass grafting; (III) controls without coronary obstructions undergoing valve replacement due to aortic stenosis and (IV) controls with healthy coronaries verified by computed tomography. The abundance and distribution of m6A and A-to-I modifications in blood RNA are charted by quantitative and qualitative methods. Selected other modified nucleosides as well as IHD candidate protein and metabolic biomarkers are measured for reference. The results of the IHD-EPITRAN study can be expected to enable identification of epitranscriptomic IHD biomarker candidates and potential drug targets.
Citation Formats
V. Sikorski et al., “Epitranscriptomics of ischemic heart disease-the IHD-EPITRAN study design and objectives,” pp. 0–0, 2021, Accessed: 00, 2021. [Online]. Available: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85108681268&origin=inward.